| 品牌 | 货号 | 包装单位 | 货期 | CAS | 产品名称 | 质量规格 | 单价(¥) | 购买数量 | 
|---|---|---|---|---|---|---|---|---|
| 罗恩 | R010038-25mg | 25mg | 5~7个工作日 | 13957-31-8 | 4-巯基尿苷 4-Thiouridine | 98% |  |  | 
| 罗恩 | R010038-5mg | 5mg | 5~7个工作日 | 13957-31-8 | 4-巯基尿苷 4-Thiouridine | 98% |  |  | 
| 罗恩 | R010038-100mg | 100mg | 5~7个工作日 | 13957-31-8 | 4-巯基尿苷 4-Thiouridine | 98% |  |  | 
| 阿拉丁 | T122953-5mg | 5mg | 现货 | 13957-31-8 | 4-巯基尿苷 (4sU) 4-Thiouridine (4sU) | Moligand™, ≥98% |  |  | 
| 阿拉丁 | T122953-25mg | 25mg | 现货 | 13957-31-8 | 4-巯基尿苷 (4sU) 4-Thiouridine (4sU) | Moligand™, ≥98% |  |  | 
| 阿拉丁 | T122953-100mg | 100mg | 现货 | 13957-31-8 | 4-巯基尿苷 (4sU) 4-Thiouridine (4sU) | Moligand™, ≥98% |  |  | 
| 阿拉丁 | T122953-500mg | 500mg | 现货 | 13957-31-8 | 4-巯基尿苷 (4sU) 4-Thiouridine (4sU) | Moligand™, ≥98% |  |  | 
| 韶远 | SY072544-1g | 1g | 现货 | 13957-31-8 | 4-硫代尿苷 4-Thiouridine | ≥98% |  |  | 
| 阿法埃莎 | Y10209-25mg | 25mg | 现货 | 13957-31-8 | 4-巯基尿苷 4-Thiouridine,98% | 98% |  |  | 
| 阿法埃莎 | Y10209-100mg | 100mg | 现货 | 13957-31-8 | 4-巯基尿苷 4-Thiouridine,98% | 98% |  |  | 
| 阿法埃莎 | Y10209-250mg | 250mg | 现货 | 13957-31-8 | 4-巯基尿苷 4-Thiouridine,98% | 98% |  |  | 
| 阿法埃莎 | Y10209-1g | 1g | 现货 | 13957-31-8 | 4-巯基尿苷 4-Thiouridine,98% | 98% |  |  | 
| 毕得 | BD100438-250mg | 250mg | 现货 | 13957-31-8 | 1-((2R,3R,4S,5R)-3,4-二羟基-5-(... 1-((2R,3R,4S,5R)-3,4-Dihydro... | 95% |  |  | 
| 毕得 | BD100438-1g | 1g | 现货 | 13957-31-8 | 1-((2R,3R,4S,5R)-3,4-二羟基-5-(... 1-((2R,3R,4S,5R)-3,4-Dihydro... | 95% |  |  | 
| 毕得 | BD100438-100mg | 100mg | 现货 | 13957-31-8 | 1-((2R,3R,4S,5R)-3,4-二羟基-5-(... 1-((2R,3R,4S,5R)-3,4-Dihydro... | 95% |  |  | 
| 毕得 | BD100438-5g | 5g | 现货 | 13957-31-8 | 1-((2R,3R,4S,5R)-3,4-二羟基-5-(... 1-((2R,3R,4S,5R)-3,4-Dihydro... | 95% |  |  | 
| 乐研 | 1020940-100mg | 100mg | 现货 | 13957-31-8 | 4-巯基尿苷 4-Thiouridine | 98% |  |  | 
| 乐研 | 1020940-250mg | 250mg | 现货 | 13957-31-8 | 4-巯基尿苷 4-Thiouridine | 98% |  |  | 
| 乐研 | 1020940-1g | 1g | 现货 | 13957-31-8 | 4-巯基尿苷 4-Thiouridine | 98% |  |  | 
| 乐研 | 1020940-25mg | 25mg | 现货 | 13957-31-8 | 4-巯基尿苷 4-Thiouridine | 98% |  |  |